1
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholson, Martin F Savitzky, Raymond S Parker III, January 2, 1996: US05480883 (166 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


2
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons: Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, January 20, 1998: US05710158 (144 worldwide citation)

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


3
Alfred P Spada, Martin P Maquire, Paul E Persons, Michael R Myers: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholsen, Martin F Savitzky, Raymond S Parker III, April 25, 1995: US05409930 (127 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


4
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons: Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 24, 1998: US05721237 (110 worldwide citation)

This invention relates to a method for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cyclic aryl, heter ...


5
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, July 8, 1997: US05646153 (106 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


6
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 3, 1998: US05714493 (79 worldwide citation)

This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.


7
Alfred P Spada, Cynthia A Fink, Michael R Myers: Compounds having antihypertensive and anti-ischemic properties. Rhone Poulenc Rorer Pharmaceuticals, Paul R Darkes, Martin F Savitzky, November 15, 1994: US05364862 (78 worldwide citation)

This invention relates to adenosine derivatives and analogs which possess adenosine agonist activity and are useful as anti-hypertensive and anti-ischemic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension and myocardial ischemia, and to method ...


8
Alfred P Spada, Cynthia A Fink, Michael R Myers: Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties. Rhone Poulenc Rorer Pharmaceuticals, Paul R Darkes, Martin F Savitzky, October 1, 1996: US05561134 (71 worldwide citation)

Compounds of the Formula ##STR1## wherein: K is N or N.fwdarw.O; Q is CH.sub.2 or O; T is ##STR2## or R.sub.3 O--CH.sub.2 ; X is a straight or branched chain alkylene, cycloalkylene or cycloalkenylene group, each of which is optionally substituted by at least one CH.sub.3, CH.sub.3 CH.sub.2, Cl, F, ...


9
Alfred P Spada, Martin P Maguire, Paul E Persons, Michael R Myers: Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, August 12, 1997: US05656643 (65 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


10
Alfred P Spada, Cynthia A Fink, Michael R Myers, Laurence W Reilly, Benoit J Vanasse: DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, Martin F Savitzky, Paul R Darkes, July 29, 1997: US05652366 (51 worldwide citation)

This invention relates to di[(1 R)-(-)-camphosulfonic acid) salt of [1S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-chloro-2-thienyl )-1-ethylethyl]amino]3 H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide , and a process for preparing the compound, comprising reac ...